Preliminary data from the first prospective clinical trial shows higher blood-based tumor burden works as biomarker for effective atezoli-zumab treatment in non-small cell lung cancer patients.
A study presented at the USCAP 2018 Annual Meeting finds that insulinoma-associated protein 1 (INSM1) is a reliable marker for the diagnosis of neuroendocrine lung tumors, including small-cell lung carcinoma.
A computer-assisted analysis of digital tissue microarray slides could soon help identify which NSCLC patients are likely to face early recurrence.
In addition to determining the probability of finding N2 or N3 disease on EBUS-TBNA the model is also able to predict the presence of mediastinal disease when EBUS-TBNA nodal sampling is negative.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The potential for molecular biomarkers to tip the balance from benefit to harm in lung cancer screening and nodule diagnosis and to enhance risk prediction warrants a robust discussion about how we determine their accuracy and readiness for clinical use.
Based on our experience at Cleveland Clinic, we favor centralized management of screening decisions in our health system, detailed and thorough shared decision-making visits with one-year follow up and concrete plans for managing incidental findings.
Primary care physicians play a vital role in detecting cancers at earlier stages. Lung cancer has the highest mortality rate of any cancer in the U.S., and screening can be controversial.
A new document advises physicians on using SBRT for high-risk scenarios involving tumor size and location and previous treatments for lung cancer in medically inoperable patients.
Vamsidhar Velcheti, MD, and his team are pursuing novel, targeted therapies for patients with a rare form of NSCLC.
The low-dose chest CT scan used for lung cancer screening frequently demonstrates incidental findings in the anatomic structures imaged from the neck to the upper abdomen. This study describes the frequency of incidental findings and their clinical and financial downstream effects.